Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.
From rns 8 Feb
"The Company looks forward to providing the market with a detailed business update later this month once definitive clinical data from the lateral flow test evaluation is available."
Once definitive clinical data....etc. Appears to me the t/u will include the conclusive detail we anxiously await.
Once proven avacta's ltd will be used testing against a range of viruses. If we do build a 'supertest' with mologic, even better. Whether covid or not, our tests will be used w/w for many years to come.
The technology avacta offers is disruptive & without doubt will shake up the market. Other, better, techs will eventually emerge, but will need a platform to demonstrate their advantage...... we have covid. AS has seized the opportunity & will develop the entire avacta offering at pace, not in the way envisaged prior to covid.
What an investment!!!
All depends on 'official' news, only a sustained rise when received. Until then, the snippets of news we've had will bring out the traders in force. Can see ncyt (e.g.) taking an initial hit as traders sell, then buy avct, then later vice versa. Tomorrow could be a roller-coaster. If the t/u drops without comments on the lft/bams think the Market will be 'confused'.
What does 'exquisite' mean in the context used? Just some possibilities:
2. extraordinarily fine
3. intense; acute
4. of rare excellence of execution
5. keenly or delicately sensitive or responsive
6. of particular refinement or elegance
7. carefully sought out, chosen, or made
Wolves, as usual we are dependent on others. If they have indicated a timeline all AS can do is repeat it. As we have seen, avct is totally dependent on the ability of others to deliver.
Sad position to be in when you have the most promising 'disruptive' technology.
Soleboy, appreciate what said, but do both groups have the ce mark? My understanding is only mologic do at this time. As per rns 26 Jan
"Abingdon is pleased to report that one of its international contract service customers has received a CE mark for professional use for its COVID-19 lateral flow antigen test"
It does, & no mention of abdx. However, from the 26 Jan rns
"Contract manufacturing for partners
Abingdon is pleased to report that one of its international contract service customers has received a CE mark for professional use for its COVID-19 lateral flow antigen test. The Company is now working closely with this partner regarding the scale-up of manufacturing to meet anticipated demand for this test. Furthermore, the Company continues to work with a number of other COVID-19 antigen test contract service partners with products in development."
They are probably working with mologic (who recently obtained a ce mark). Additionally, with other partners - with tests in development.
We also know abdx have opened a new factory capable of greatly increased production.
Mentioned or not in the news, I'm pretty confident they will soon be producing at full capacity.